CHRF is concerned that continued and unpredictable changes to the regulatory environment and increasing efforts to achieve significant price reductions for pharmaceuticals in Canada could be impacting pharmaceutical company decisions about whether to continue investing in Canada’s health research ecosystem.
In this context, CHRF recommends that the PMPRB halt its planned changes to its Guidelines and avoid any additional regulatory initiatives until an impact assessment has been conducted.
Read our full submission:
CHRF_PMPRB Guidelines Submission_Final
.pdf
Download PDF • 474KB